Network pharmacology and experimental verification reveal the mechanism of Qingfei Tongluo mixture in treating pulmonary fibrosis
Background: Pulmonary fibrosis (PF) is a chronic interstitial lung disease posing significant health risks. This study aimed to investigate the therapeutic mechanism of Qingfei Tongluo mixture (QTm) in treating PF by combining network pharmacology and experimental verification. Results: A total of 2...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Electronic Journal of Biotechnology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0717345824000307 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841546012764667904 |
|---|---|
| author | Ying Zhou Wenlong Wang Wanping Zhu Tingting Cai Nannan Wang Xia Liu Wenmin Wang Kequn Chai |
| author_facet | Ying Zhou Wenlong Wang Wanping Zhu Tingting Cai Nannan Wang Xia Liu Wenmin Wang Kequn Chai |
| author_sort | Ying Zhou |
| collection | DOAJ |
| description | Background: Pulmonary fibrosis (PF) is a chronic interstitial lung disease posing significant health risks. This study aimed to investigate the therapeutic mechanism of Qingfei Tongluo mixture (QTm) in treating PF by combining network pharmacology and experimental verification. Results: A total of 246 active ingredients in QTm were identified, with 159 potential targets for PF treatment. Quercetin, a key active ingredient, was associated with the TGF-β1 signaling pathway. Gene Ontology and KEGG enrichment analyses identified 42 core genes, with a notable implication of the TGF-beta signaling pathway in PF. Immunohistochemistry showed elevated FTO and TGF-β1 levels in PF tissues. Animal experiments demonstrated that QTm improved alveolar structure, reduced interstitial lesions, and enhanced lung function while decreasing hydroxyproline content and the expression of FTO and TGF-β1 proteins. Conclusions: QTm may inhibit PF progression by suppressing FTO/TGF-β1 expression, thereby improving lung function. These findings suggest that QTm holds potential as a treatment for PF.How to cite: Zhou Y, Wang W, Zhu W, et al. Network pharmacology and experimental verification reveal the mechanism of Qingfei Tongluo mixture in treating pulmonary fibrosis. Electron J Biotechnol 2025;73. https://doi.org/10.1016/j.ejbt.2024.10.002. |
| format | Article |
| id | doaj-art-c42c99f12805409da1095d6f72f09288 |
| institution | Kabale University |
| issn | 0717-3458 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Electronic Journal of Biotechnology |
| spelling | doaj-art-c42c99f12805409da1095d6f72f092882025-01-11T06:38:28ZengElsevierElectronic Journal of Biotechnology0717-34582025-01-01733847Network pharmacology and experimental verification reveal the mechanism of Qingfei Tongluo mixture in treating pulmonary fibrosisYing Zhou0Wenlong Wang1Wanping Zhu2Tingting Cai3Nannan Wang4Xia Liu5Wenmin Wang6Kequn Chai7Tongde Hospital of Zhejiang Province Affiliated to Zhejiang Chinese Medical University, No. 234 Gucui Road, Hangzhou City, Zhejiang Province, ChinaTongde Hospital of Zhejiang Province Affiliated to Zhejiang Chinese Medical University, No. 234 Gucui Road, Hangzhou City, Zhejiang Province, ChinaZhejiang Provincial Key Laboratory of Traditional Chinese Medicine, No. 866, Yuhangtang Road, Xihu District, Hangzhou City, Zhejiang Province, China; Pharmacodynamic Material Basis Research of Chinese Medicine, Zhejiang Academy of Traditional Chinese Medicine, 548 Binwen Road, Binjiang District, Hangzhou City, Zhejiang Province, ChinaZhejiang Provincial Key Laboratory of Traditional Chinese Medicine, No. 866, Yuhangtang Road, Xihu District, Hangzhou City, Zhejiang Province, China; Pharmacodynamic Material Basis Research of Chinese Medicine, Zhejiang Academy of Traditional Chinese Medicine, 548 Binwen Road, Binjiang District, Hangzhou City, Zhejiang Province, ChinaZhejiang Provincial Key Laboratory of Traditional Chinese Medicine, No. 866, Yuhangtang Road, Xihu District, Hangzhou City, Zhejiang Province, China; Pharmacodynamic Material Basis Research of Chinese Medicine, Zhejiang Academy of Traditional Chinese Medicine, 548 Binwen Road, Binjiang District, Hangzhou City, Zhejiang Province, ChinaZhejiang Provincial Key Laboratory of Traditional Chinese Medicine, No. 866, Yuhangtang Road, Xihu District, Hangzhou City, Zhejiang Province, China; Pharmacodynamic Material Basis Research of Chinese Medicine, Zhejiang Academy of Traditional Chinese Medicine, 548 Binwen Road, Binjiang District, Hangzhou City, Zhejiang Province, ChinaThe Yangtze River Delta Biological Medicine Research and Development Center of Zhejiang Province, No. 9 Jiuhuan Road, Jiubao Town, Shangcheng District, Hangzhou City, Zhejiang Province, China; Yangtze Delta Region Institution of Tsinghua University, 705 Asia Pacific Road, Nanhu District, Jiaxing City, Zhejiang Province, ChinaTongde Hospital of Zhejiang Province Affiliated to Zhejiang Chinese Medical University, No. 234 Gucui Road, Hangzhou City, Zhejiang Province, China; Corresponding author.Background: Pulmonary fibrosis (PF) is a chronic interstitial lung disease posing significant health risks. This study aimed to investigate the therapeutic mechanism of Qingfei Tongluo mixture (QTm) in treating PF by combining network pharmacology and experimental verification. Results: A total of 246 active ingredients in QTm were identified, with 159 potential targets for PF treatment. Quercetin, a key active ingredient, was associated with the TGF-β1 signaling pathway. Gene Ontology and KEGG enrichment analyses identified 42 core genes, with a notable implication of the TGF-beta signaling pathway in PF. Immunohistochemistry showed elevated FTO and TGF-β1 levels in PF tissues. Animal experiments demonstrated that QTm improved alveolar structure, reduced interstitial lesions, and enhanced lung function while decreasing hydroxyproline content and the expression of FTO and TGF-β1 proteins. Conclusions: QTm may inhibit PF progression by suppressing FTO/TGF-β1 expression, thereby improving lung function. These findings suggest that QTm holds potential as a treatment for PF.How to cite: Zhou Y, Wang W, Zhu W, et al. Network pharmacology and experimental verification reveal the mechanism of Qingfei Tongluo mixture in treating pulmonary fibrosis. Electron J Biotechnol 2025;73. https://doi.org/10.1016/j.ejbt.2024.10.002.http://www.sciencedirect.com/science/article/pii/S0717345824000307FTONetwork pharmacologyPulmonary fibrosisQingfei Tongluo mixtureTGF-β1 |
| spellingShingle | Ying Zhou Wenlong Wang Wanping Zhu Tingting Cai Nannan Wang Xia Liu Wenmin Wang Kequn Chai Network pharmacology and experimental verification reveal the mechanism of Qingfei Tongluo mixture in treating pulmonary fibrosis Electronic Journal of Biotechnology FTO Network pharmacology Pulmonary fibrosis Qingfei Tongluo mixture TGF-β1 |
| title | Network pharmacology and experimental verification reveal the mechanism of Qingfei Tongluo mixture in treating pulmonary fibrosis |
| title_full | Network pharmacology and experimental verification reveal the mechanism of Qingfei Tongluo mixture in treating pulmonary fibrosis |
| title_fullStr | Network pharmacology and experimental verification reveal the mechanism of Qingfei Tongluo mixture in treating pulmonary fibrosis |
| title_full_unstemmed | Network pharmacology and experimental verification reveal the mechanism of Qingfei Tongluo mixture in treating pulmonary fibrosis |
| title_short | Network pharmacology and experimental verification reveal the mechanism of Qingfei Tongluo mixture in treating pulmonary fibrosis |
| title_sort | network pharmacology and experimental verification reveal the mechanism of qingfei tongluo mixture in treating pulmonary fibrosis |
| topic | FTO Network pharmacology Pulmonary fibrosis Qingfei Tongluo mixture TGF-β1 |
| url | http://www.sciencedirect.com/science/article/pii/S0717345824000307 |
| work_keys_str_mv | AT yingzhou networkpharmacologyandexperimentalverificationrevealthemechanismofqingfeitongluomixtureintreatingpulmonaryfibrosis AT wenlongwang networkpharmacologyandexperimentalverificationrevealthemechanismofqingfeitongluomixtureintreatingpulmonaryfibrosis AT wanpingzhu networkpharmacologyandexperimentalverificationrevealthemechanismofqingfeitongluomixtureintreatingpulmonaryfibrosis AT tingtingcai networkpharmacologyandexperimentalverificationrevealthemechanismofqingfeitongluomixtureintreatingpulmonaryfibrosis AT nannanwang networkpharmacologyandexperimentalverificationrevealthemechanismofqingfeitongluomixtureintreatingpulmonaryfibrosis AT xialiu networkpharmacologyandexperimentalverificationrevealthemechanismofqingfeitongluomixtureintreatingpulmonaryfibrosis AT wenminwang networkpharmacologyandexperimentalverificationrevealthemechanismofqingfeitongluomixtureintreatingpulmonaryfibrosis AT kequnchai networkpharmacologyandexperimentalverificationrevealthemechanismofqingfeitongluomixtureintreatingpulmonaryfibrosis |